Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Liabilities and Shareholders Equity (2016 - 2025)

Altimmune (ALT) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $279.9 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 100.95% to $279.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $846.0 million through Dec 2025, up 30.38% year-over-year, with the annual reading at $279.9 million for FY2025, 100.95% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $279.9 million at Altimmune, up from $218.4 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $279.9 million in Q4 2025, with the low at $139.3 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $203.4 million, with a median of $206.3 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity surged 387.25% in 2021, then crashed 33.87% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $218.9 million in 2021, then dropped by 5.45% to $206.9 million in 2022, then rose by 1.79% to $210.6 million in 2023, then plummeted by 33.87% to $139.3 million in 2024, then surged by 100.95% to $279.9 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $279.9 million, $218.4 million, and $190.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.